39 dead in Kenya mall attack claimed by militants

May 19: A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He added that the drug should be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.

Washington, Feb 21: US President Donald Trump has made yet another tall claim about the size of the crowd that will welcome him in Ahmedabad, saying Prime Minister Narendra Modi has told him that there will 10 million(1 crore) people to greet him on his arrival for his maiden visit to India.

President Trump and First Lady Melania are scheduled to travel to Ahmedabad, Agra and New Delhi on February 24 and 25.

Speaking to reporters at the Joint Base Andrews in Maryland on Tuesday, Trump said that Modi told him that "we'll have 7 million people between the airport and the event."

"So it's going to be very exciting. But he says between the stadium and the airport, we'll have about 7 million people. So it's going to be very exciting. I hope you all enjoy it," he said.

On Thursday, Trump upped the crowd size by three million at a 'Keep America Great' rally in Colorado.

"I hear, they are going to have 10 million people. They say anywhere from six to 10 million people are going to be showing up along the route to one of the largest stadiums in the world, the largest cricket stadium in the world, which is brand new and beautiful," said Trump, who is seeking reelection in the November presidential polls.

But according to a top civic official in Ahmedabad, the total population of the city is only around 70 lakh.

The authorities believe that between one to two lakh people are expected to line up along the 22-km route of the road show by Modi and Trump from the airport to the Motera cricket stadium, said to be the world's largest.

"We believe that around one to two lakh people will gather to welcome the dignitaries during the road show," Ahmedabad Municipal Commissioner Vijay Nehra said on Thursday, contradicting the claims made by the US President.

As per the road show route plan, Trump and Modi will first reach the Sabarmati Ashram, a place closely associated with Mahatma Gandhi, from Ahmedabad airport.

Addressing his supporters, Trump spoke about his India visit and said the "Namaste Trump" rally in Ahmedabad would spoil him.

"Prime Minister Modi said, we will have 10 million people greet you. Here's my problem. We have a packed house. We have a lot of people, thousands of people that couldn't get in. It's going to look like peanuts from now on," he said.

"I'll never be satisfied with the crowd. If we have 10 million people in India, how can I be satisfied when we fill up like a 60,000-seat stadium? I am getting spoiled," Trump said.

One of Trump's supporters from the audience then suggested that he build a bigger stadium.

Washington, Jun 13: America's first-ever Hindu lawmaker Tulsi Gabbard has said that in this chaotic time, one can find certainty, strength, and peace in Bhagavad Gita.

In her message during a virtual commencement address, the 39-year-old Congresswoman from Hawaii said that it is a chaotic time and no one can say with certainty what tomorrow looks like.

"... but we find certainty, strength, and peace in the practice of Bhakti Yoga and Karma Yoga taught to us by Krishna in the Bhagavad Gita," Tulsi Gabbard told the 'Class of 2020 for Hindu students''.

Her address came amidst protests in the US against the killing of African-American George Floyd by a white police officer in Minneapolis.

The country has been swept by protests since George Floyd's custodial death on May 25 with thousands of people mounting pressure for changes to the law enforcement practices.

The first-ever virtual Hindu commencement was organised by the Hindu Students Council on June 7, which drew thousands of viewers on Facebook and YouTube Live, all coming together in solidarity during the ongoing COVID-19 crisis.

According to Johns Hopkins Coronavirus Resource Center, the contagion has infected over 76,00,000 people and killed more than 4,25,000 across the world. The US is the worst affected country with over 2.04 million cases and more than 1,14,000 deaths.

The COVID-19, which originated in China''s Wuhan city in December last year, has also battered the world economy with the International Monetary Fund saying that the global economy is bound to suffer a "severe recession".

Scientists are racing against time to find a vaccine or medicine for its treatment.

Hundreds of graduates from the US, Canada, the UK, India and Australia attended to commemorate their graduation in a unique way - by celebrating their shared Hindu values.

Professor Subhash Kak served as the ceremony's Grand Marshall.

"As you think about this new chapter in your lives, ask yourself what is my purpose in life? It is a deep question that if you can recognise now that your purpose is to serve God and God''s children, practicing Karma Yoga, then you can lead a truly successful life," Tulsi Gabbard said.

"Success is not defined by temporary material things, trinkets, glittery objects or accomplishments - but a deeply successful and happy life centered around service," she added.

The Iraq war veteran ended her presidential campaign in March and offered her full support to former vice president Joe Biden, 77, who is all set to challenge Republican incumbent Donald Trump, 73, in November elections.

The commencement address focused heavily on themes from the Bhagavad Gita, a timeless historical text that many Hindus consider their moral framework.

Professor Kak, Regent Professor at Oklahoma State University and 2019 Padma Shri recipient, read out the names of the graduating students.

"I exhort you - the graduating students - to be the leaders of the new world where education is less of the mind of a vessel to be filled with information (usually forgotten after the semester is over), and more of a flame that is lit as envisioned by our Vedic sages," he said.

The student speakers were from many university campuses, including the Massachusetts Institute of Technology, Princeton, and Stanford.

Listen to the latest songs, only on JioSaavn.com

The programme included offerings of Hindu prayers, recitation of a traditional graduation message from the Upanishads, and a symbolic conferral of degrees to high school and college graduate.

Founded in 1990, Hindu Students Council is North America''s largest pan-Hindu youth organisation.